305 related articles for article (PubMed ID: 21690253)
1. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.
Pilati C; Amessou M; Bihl MP; Balabaud C; Nhieu JT; Paradis V; Nault JC; Izard T; Bioulac-Sage P; Couchy G; Poussin K; Zucman-Rossi J
J Exp Med; 2011 Jul; 208(7):1359-66. PubMed ID: 21690253
[TBL] [Abstract][Full Text] [Related]
2. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.
Pilati C; Zucman-Rossi J
Cytokine Growth Factor Rev; 2015 Oct; 26(5):499-506. PubMed ID: 26188635
[TBL] [Abstract][Full Text] [Related]
3. Recurrent chromosomal rearrangements of
Bayard Q; Caruso S; Couchy G; Rebouissou S; Bioulac Sage P; Balabaud C; Paradis V; Sturm N; de Muret A; Guettier C; Bonsang B; Copie C; Letouzé E; Calderaro J; Imbeaud S; Nault JC; Zucman-Rossi J
Gut; 2020 Sep; 69(9):1667-1676. PubMed ID: 31907296
[TBL] [Abstract][Full Text] [Related]
4. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.
Nault JC; Fabre M; Couchy G; Pilati C; Jeannot E; Tran Van Nhieu J; Saint-Paul MC; De Muret A; Redon MJ; Buffet C; Salenave S; Balabaud C; Prevot S; Labrune P; Bioulac-Sage P; Scoazec JY; Chanson P; Zucman-Rossi J
J Hepatol; 2012 Jan; 56(1):184-91. PubMed ID: 21835143
[TBL] [Abstract][Full Text] [Related]
5. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
Rebouissou S; Amessou M; Couchy G; Poussin K; Imbeaud S; Pilati C; Izard T; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
Nature; 2009 Jan; 457(7226):200-4. PubMed ID: 19020503
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.
Poussin K; Pilati C; Couchy G; Calderaro J; Bioulac-Sage P; Bacq Y; Paradis V; Leteurtre E; Sturm N; Ramos J; Guettier C; Bardier-Dupas A; Boulai A; Wendum D; Selves J; Izard T; Nault JC; Zucman-Rossi J
Oncoimmunology; 2013 Dec; 2(12):e27090. PubMed ID: 24501689
[TBL] [Abstract][Full Text] [Related]
7. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling.
Sommer J; Effenberger T; Volpi E; Waetzig GH; Bernhardt M; Suthaus J; Garbers C; Rose-John S; Floss DM; Scheller J
J Biol Chem; 2012 Apr; 287(17):13743-51. PubMed ID: 22523320
[TBL] [Abstract][Full Text] [Related]
8. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Kim H; Baumann H
Mol Cell Biol; 1999 Aug; 19(8):5326-38. PubMed ID: 10409724
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.
Calderaro J; Nault JC; Balabaud C; Couchy G; Saint-Paul MC; Azoulay D; Mehdaoui D; Luciani A; Zafrani ES; Bioulac-Sage P; Zucman-Rossi J
Mod Pathol; 2016 Jan; 29(1):43-50. PubMed ID: 26516697
[TBL] [Abstract][Full Text] [Related]
10. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.
Calderaro J; Labrune P; Morcrette G; Rebouissou S; Franco D; Prévot S; Quaglia A; Bedossa P; Libbrecht L; Terracciano L; Smit GP; Bioulac-Sage P; Zucman-Rossi J
J Hepatol; 2013 Feb; 58(2):350-7. PubMed ID: 23046672
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a Chinese cohort.
Sun L; Sui L; Cong X; Ma K; Ma X; Huang Y; Fan C; Fu X; Ma K
Cancer Genet; 2014; 207(7-8):291-8. PubMed ID: 25242236
[TBL] [Abstract][Full Text] [Related]
13. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Gao SP; Mark KG; Leslie K; Pao W; Motoi N; Gerald WL; Travis WD; Bornmann W; Veach D; Clarkson B; Bromberg JF
J Clin Invest; 2007 Dec; 117(12):3846-56. PubMed ID: 18060032
[TBL] [Abstract][Full Text] [Related]
15. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
Nault JC; Couchy G; Balabaud C; Morcrette G; Caruso S; Blanc JF; Bacq Y; Calderaro J; Paradis V; Ramos J; Scoazec JY; Gnemmi V; Sturm N; Guettier C; Fabre M; Savier E; Chiche L; Labrune P; Selves J; Wendum D; Pilati C; Laurent A; De Muret A; Le Bail B; Rebouissou S; Imbeaud S; ; Bioulac-Sage P; Letouzé E; Zucman-Rossi J
Gastroenterology; 2017 Mar; 152(4):880-894.e6. PubMed ID: 27939373
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
17. STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway.
He J; Shi J; Xu X; Zhang W; Wang Y; Chen X; Du Y; Zhu N; Zhang J; Wang Q; Yang J
J Biosci; 2012 Jun; 37(2):243-57. PubMed ID: 22581330
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
[TBL] [Abstract][Full Text] [Related]
19. Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.
Ryu J; Kang M; Lee MS; Kim HJ; Nam SH; Song HE; Lee D; Lee JW
Mol Cell Biol; 2014 Aug; 34(16):2946-60. PubMed ID: 24912675
[TBL] [Abstract][Full Text] [Related]
20. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
